Verdence Capital Advisors LLC Has $264,000 Position in GE HealthCare Technologies Inc. $GEHC

Verdence Capital Advisors LLC reduced its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 4.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,563 shares of the company’s stock after selling 159 shares during the period. Verdence Capital Advisors LLC’s holdings in GE HealthCare Technologies were worth $264,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in GE HealthCare Technologies by 49.9% during the first quarter. JPMorgan Chase & Co. now owns 5,140,549 shares of the company’s stock worth $414,894,000 after purchasing an additional 1,711,963 shares during the last quarter. Nuveen LLC acquired a new position in shares of GE HealthCare Technologies during the 1st quarter worth about $77,058,000. Eminence Capital LP boosted its stake in shares of GE HealthCare Technologies by 38.7% during the 1st quarter. Eminence Capital LP now owns 1,819,129 shares of the company’s stock worth $146,822,000 after buying an additional 507,101 shares during the last quarter. Homestead Advisers Corp boosted its stake in shares of GE HealthCare Technologies by 92.7% during the 1st quarter. Homestead Advisers Corp now owns 988,600 shares of the company’s stock worth $79,790,000 after buying an additional 475,500 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in shares of GE HealthCare Technologies by 15.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 3,111,398 shares of the company’s stock worth $251,121,000 after buying an additional 409,636 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $73.38 on Friday. The firm has a 50-day moving average of $74.47 and a 200-day moving average of $72.12. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.93 and a current ratio of 1.16. The stock has a market cap of $33.50 billion, a PE ratio of 15.04, a P/E/G ratio of 2.80 and a beta of 1.13. GE HealthCare Technologies Inc. has a 52-week low of $57.65 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.15. GE HealthCare Technologies had a return on equity of 23.93% and a net margin of 11.22%.The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.96 billion. During the same period last year, the firm posted $1.00 EPS. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2025 guidance at 4.430-4.630 EPS. On average, sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current year.

GE HealthCare Technologies Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 14th. Shareholders of record on Friday, October 24th will be paid a $0.035 dividend. The ex-dividend date is Friday, October 24th. This represents a $0.14 annualized dividend and a yield of 0.2%. GE HealthCare Technologies’s payout ratio is 2.87%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Weiss Ratings reissued a “hold (c+)” rating on shares of GE HealthCare Technologies in a research report on Tuesday. Zacks Research downgraded GE HealthCare Technologies from a “strong-buy” rating to a “hold” rating in a report on Monday, September 29th. Citigroup cut shares of GE HealthCare Technologies from a “buy” rating to a “neutral” rating and cut their price target for the company from $93.00 to $83.00 in a research note on Tuesday, October 7th. Morgan Stanley set a $74.00 target price on shares of GE HealthCare Technologies in a research note on Thursday, September 18th. Finally, Wall Street Zen downgraded shares of GE HealthCare Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, September 20th. Six analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.20.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.